Preparation and application of anti-tumor fermentation product of anti-pseudomonas FD6 rpoS mutant strain
By fermenting the Pseudomonas proteins FD6 rpoS mutant strain under different carbon source conditions, a high-yield crude fermentation broth extract was prepared, which solved the unclear problem of the biosynthesis regulation mechanism of antibacterial active ingredients and achieved significant inhibition of tumor cells. Effects, an effective anti-tumor pharmaceutical composition is provided.
Patent Information
- Application Number
- CN202411205680.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-30
- Publication Date
- 2024-12-06
AI Technical Summary
In the prior art, the biosynthesis regulation mechanism of the rpoS gene mutant strain of the Pseudomonas proteins bacteria against the antibacterial active components 2,4-diacetylphthoglucoside and pyozoa aeruginosa is not fully understood, and other chemical components of the organisms The synthesis effect is unknown, making it difficult to effectively prepare high yields of anti-tumor fermentation products.
The Pseudomonas proteins FD6 rpoS mutant strain was cultured in LB medium, inoculated into TSB basal medium with different carbon sources for fermentation, the supernatant was collected and extracted with ethyl acetate, and concentrated under reduced pressure to prepare a high yield of Pseudomonas proteins FD6. RpoS mutant strain fermentation broth crude extract is used for the development of anti-tumor drugs.
Significantly increased the yield of 2,4-diacetyl phlogenesis and pylori aeruginosa and demonstrated significant proliferation inhibition on non-small cell lung cancer cell line A549, providing an effective anti-tumor drug Composition.
Smart Images

Figure CN119082210A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of microbial pharmacy, and specifically relates to the preparation and application of anti-tumor fermentation products of Pseudomonas protegens FD6 rpoS mutant strain. Background Art
[0002] Pseudomonas bacteria can produce abundant secondary metabolites, some of which have good antibacterial activity and have been commercialized and widely used in clinical and agricultural fields, such as pyrrolnitrin (PRN) and mupirocin. Pseudomonas protegens FD6 is a bacterium isolated from the rhizosphere of Qingkou Qingcai in Minhou, Fujian Province. Whole genome sequencing showed that there are 17 biosynthetic gene clusters in its genome, involving the biosynthesis of secondary metabolites such as 2,4-diacetylphloroglucinol (2,4-DAPG), pyoluteorin (PLT), and pyrrolnitrin (PRN). It has been found that P.protegens FD6 can produce antibacterial active ingredients such as 2,4-diacetylphloroglucinol, pyrrolidine, pyocyanin, hydrocyanic acid and cyclolipeptide orfamide A, as well as chemical components such as Aerugine, Salicylamide, cyclo-(cis-L-Phe-D-4-OH-Pro), cyclo(Gly-Pro), and cyclo-(L-Ala-L-4-OH-Pro).
[0003] The RpoS protein encoded by the rpoS gene is a type of non-essential sigma factor that can regulate the synthesis of secondary metabolites, and the regulation mode is different in different strains. The rpoS gene mutant of P.fluorescens Pf-5 has a decreased production of pyrrolidine (PRN), but an increased production of 2,4-diacetylphloroglucinol (2,4-DAPG) and pyocyanin (PLT); while the rpoS gene deletion mutation of P.chlororaphis O6 reduces its hydrocyanic acid production and increases its production of phenazine compounds. Studies have found that compared with the wild-type strain FD6, the production of 2,4-diacetylphloroglucinol (2,4-DAPG) and pyocyanin (PLT) in the FD6 rpoS gene deletion mutant increased significantly, by about 25 times and 30 times, respectively. The rpoS gene in FD6 negatively regulates the biosynthesis of the antimicrobial active ingredients 2,4-DAPG and PLT, but its effect on the biosynthesis of other chemical components remains to be studied. Summary of the invention
[0004] The present invention provides a crude extract of fermentation broth of a P. protegens FD6 rpoS mutant, which is characterized by being prepared by the following method:
[0005] (1) A single colony of the P. protegens FD6 rpoS mutant was inoculated into LB medium and cultured at 28°C and 180 rpm for 24 h to obtain a seed solution for later use;
[0006] (2) inoculating the seed solution obtained in step (1) into TSB basal medium supplemented with different carbon sources at an inoculum rate of 1‰, and culturing at room temperature to 30°C for 36-60 hours to obtain a fermentation broth;
[0007] (3) The fermentation broth obtained in step (2) is centrifuged at 4° C. and 9000-10000 rpm for 10-15 min, the supernatant is collected, extracted with ethyl acetate 2-3 times, and concentrated under reduced pressure to obtain the crude extract of the fermentation broth of the P. protegens FD6 rpoS mutant strain.
[0008] The formula of the TSB basal medium is 15g of tryptone, 5g of soy peptone, and 5g of NaCl per liter of water, with a pH of 7.0-7.2. The carbon source is selected from one of sucrose, lactose, maltose, glucose, glycerol, and sodium citrate, and the amount of the carbon source is 2%-3% of the mass of the basal medium. The carbon source is preferably maltose or glycerol.
[0009] The yield of the crude extract of the fermentation broth of the P.protegens FD6 rpoS mutant strain is 176.9±9.6 mg / L in sucrose medium, 209.7±8.5 mg / L in lactose medium, 271.2±2.3 mg / L in maltose medium, 193.8±5.6 mg / L in glucose medium, 402.5±10.5 mg / L in glycerol medium, and 127.1±2.3 mg / L in sodium citrate medium.
[0010] The crude extract of the fermentation broth of the P. protegens FD6 rpoS mutant 1 The H-NMR diagram is basically as follows Figure 3 shown.
[0011] The LC-MS graph of the crude extract of the fermentation broth of the P. protegens FD6 rpoS mutant is basically as follows Figure 4 shown.
[0012] Another embodiment of the present invention provides a method for preparing the crude extract of the fermentation broth of the P.protegens FD6 rpoS mutant strain, which is characterized by comprising the following steps:
[0013] (1) A single colony of the P. protegens FD6 rpoS mutant was inoculated into LB medium and cultured at 28°C and 180 rpm for 24 h to obtain a seed solution for later use;
[0014] (2) The seed liquid obtained in step (1) is inoculated into TSB basal medium supplemented with different carbon sources at an inoculum amount of 1‰, and cultured at room temperature to 30°C for 36-60 hours to obtain a fermentation liquid.
[0015] (3) The fermentation broth obtained in step (2) is centrifuged at 4° C. and 9000-10000 rpm for 10-15 min, the supernatant is collected, extracted with ethyl acetate 2-3 times, and concentrated under reduced pressure to obtain the crude extract of the TSB basic medium fermentation broth with different carbon sources added.
[0016] The formula of the TSB basic culture medium is 15g of tryptone, 5g of soy peptone, 5g of NaCl per liter of water, pH=7.0-7.2. The carbon source is selected from one of sucrose, lactose, maltose, glucose, glycerol, and sodium citrate, and the amount of the carbon source is 2%-3% of the mass of the basic culture medium.
[0017] Another embodiment of the present invention provides the use of the crude extract of the fermentation broth of the P. protegens FD6 rpoS mutant in the preparation of anti-tumor drugs. The tumor is preferably a human non-small cell lung cancer cell line A549.
[0018] Another embodiment of the present invention provides a composition, characterized in that the composition uses the crude extract of the fermentation broth of the P.protegens FD6rpoS mutant as an effective ingredient. The composition may also include other anti-tumor drugs. The composition may also include a pharmaceutically acceptable salt. The dosage form of the composition is selected from a solid preparation, a liquid preparation or a semi-solid preparation.
[0019] The formula of the LB culture medium of the present invention is as follows: 5.0 g of yeast powder, 10.0 g of tryptone, 10.0 g of NaCl per liter of water, and pH=7.0-7.2.
[0020] The "P.protegens FD6 rpoS mutant" of the present invention is obtained by gene knockout of "Pseudomonas protegens FD6". "Pseudomonas protegens FD6", referred to as "P.protegens FD6", is a bacterium isolated from the rhizosphere of Qingkou Qingcai in Minhou, Fujian Province, and its ITS sequence has been submitted to the NCBI website, with a GenBank number of CP031396. P.protegens FD6 has been disclosed in the inventor's previous research paper "Australasian Plant Pathology, 2020, 49: 307-317", and "P.protegens FD6 rpoS mutant" has been disclosed in the inventor's previous research paper "Frontiers in Microbiology, 2022, 13: 993732", and the above two strains have been preserved in the College of Horticulture and Plant Protection of Yangzhou University where the applicant is located. The public can obtain P.protegens FD6 and P.protegens FD6 rpoS mutant according to the methods recorded in the above research papers of the inventor, or purchase them from the College of Horticulture and Plant Protection of Yangzhou University where the applicant is located. The applicant promises that the College of Horticulture and Plant Protection of Yangzhou University can provide P.protegens FD6 and P.protegens FD6rpoS mutant to the public 20 years from the date of application of this invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 This is a graph of the fermentation yield of the P.protegens FD6 rpoS mutant.
[0022] Figure 2 This is the TLC graph of the crude extract of the fermentation broth of P.protegens FD6 rpoS mutant (TSB medium was supplemented with different carbon sources) (A) developing solvent: chloroform-methanol (v:v) 20:1; (B) developing solvent: chloroform-methanol (v:v) 10:1.
[0023] Figure 3 It is the crude extract of the fermentation broth of P.protegens FD6 rpoS mutant 1 H-NMR chart (DMSO-d6, 600 MHz).
[0024] Figure 4 LC-MS graph of crude extract of fermentation broth of P.protegens FD6 rpoS mutant: (A) XWC graph (254 nm); (B) BPC graph.
[0025] Figure 5 The figure shows the inhibitory effect of the crude extract of the fermentation broth of P. protegens FD6 ropS mutant on the proliferation of A549 cells. (A) Maltose-TSB medium; (B) Glycerol-TSB medium; (C) Positive control cisplatin. DETAILED DESCRIPTION
[0026] In order to facilitate further understanding of the present invention, the following examples are provided to illustrate it in more detail. However, these examples are only for better understanding of the invention and are not intended to limit the scope or implementation principles of the present invention. The implementation methods of the present invention are not limited to the following contents.
[0027] Example 1 Liquid fermentation of Pseudomonas protegens FD6 rpoS mutant and analysis of chemical components of fermentation broth 1 Instruments and materials
[0028] Quantum-I plus 600MHz nuclear magnetic resonance instrument (Wuhan Zhongke Oxford Spectroscopy Technology Co., Ltd.); TripleTOF 4600 ultra-high performance liquid chromatography-quadrupole tandem time-of-flight mass spectrometer (AB SCIEX, USA); SHP-250 constant temperature incubator (Shanghai Jinghong Experimental Equipment Co., Ltd.); SKY-200B constant temperature oscillating shaker (Shanghai Sukun Industrial Co., Ltd.), etc.
[0029] Silica gel 60F254 aluminum plate (20 cm × 20 cm), mass spectrometry methanol (Merck, Germany); Atlantis T3 chromatographic column (2.1 mm × 100 mm, 3 μm) (Waters, USA); DMSO-d6 (Cambridge Isotope Laboratories, USA); glucose, sucrose, sodium chloride, glycerol, ethyl acetate, K2HPO4, MgSO4·7H2O, lactose, maltose, chloroform, methanol (analytical grade, Sinopharm Chemical Reagent Co., Ltd.); yeast powder (biochemical reagent, Beijing Aoboxing Biotechnology Co., Ltd.); trypsin (biochemical reagent, Shanghai Bowei Microbiology Technology Co., Ltd.), etc.
[0030] 2. Strain origin and fermentation
[0031] Pseudomonas protegens FD6 (GenBank No.: CP031396) was isolated from the rhizosphere of Qingkou vegetable in Minhou, Fujian Province, and is now stored in the College of Horticulture and Plant Protection of Yangzhou University. The rpoS gene deletion mutant of P. protegens FD6 was constructed by gene knockout.
[0032] (1) A single colony of the freshly activated FD6 rpoS mutant was selected and inoculated into LB medium (5.0 g yeast powder, 10.0 g tryptone, 10.0 g NaCl, 1000 mL water, pH = 7.0-7.2), and cultured at 28°C and 180 rpm for 24 h to obtain seed solution for later use.
[0033] (2) Fermentation medium: TSB medium (15 g tryptone, 5 g soy peptone, 5 g NaCl, 1000 mL water, pH = 7.0-7.2) was used as the basal medium, and different carbon sources (sucrose, lactose, maltose, glucose, glycerol, sodium citrate) were added in an amount of 2% (2% of the mass of TSB basal medium).
[0034] (3) The seed liquid was inoculated into TSB medium supplemented with different carbon sources at an inoculum size of 1‰. 400 mL of the medium was placed in a 1000 mL Erlenmeyer flask and cultured at 28°C and 180 rpm for 48 h. Three bottles of each medium were fermented in parallel.
[0035] (4) The fermentation broth was centrifuged at 4°C and 9000 rpm for 10 min, the supernatant was collected, extracted with ethyl acetate three times, and concentrated under reduced pressure to obtain a crude extract of the fermentation broth. The yields of the fermentation products in each culture medium were: sucrose medium 176.9±9.6 mg / L, lactose medium 209.7±8.5 mg / L, maltose medium 271.2±2.3 mg / L, glucose medium 193.8±5.6 mg / L, glycerol medium 402.5±10.5 mg / L, sodium citrate medium 127.1±2.3 mg / L ( Figure 1 ).
[0036] 3. Fermentation broth crude extract 1 H-NMR analysis
[0037] (1) TLC analysis of crude extract from fermentation broth of P. protegens FD6 rpoS mutant
[0038] Thin layer chromatography (TLC) analysis showed that the parallel fermentation products of the six culture media had basically the same thin layer spots, and the fermentation was relatively stable ( Figure 2 ).like Figure 2 As shown in A, under the UV analyzer at 254nm, the crude extracts of the six fermentation broths were f 0.55, R f 0.45, R f 0.27, R f There are obvious spots at 0.18, but when lactose, maltose and glycerol are carbon sources, their R fThe spot at 0.45 may be two overlapping spots. In addition, the crude extract of TSB-glucose fermentation broth is f There is an obvious spot at 0.15; Figure 2 As shown in B, under the UV analyzer at 254nm, the crude extracts of the six fermentation broths were f A new spot clearly appears at 0.09.
[0039] (2) Crude extract of fermentation broth of P. protegens FD6 rpoS mutant 1 H-NMR spectrum analysis
[0040] The crude extract of each culture medium fermentation broth was sampled (about 50 mg) and dissolved in DMSO-d6. Quantum-I plus 600MHz NMR was used for determination 1 H-NMR spectra, processed by MestReNova 14.0 software 1 H-NMR spectrum. Figure 3 As shown in the figure, when sucrose, lactose, maltose, glycerol, glucose and sodium citrate were added to TSB medium as carbon sources, the chemical components of the crude extract of fermentation broth were relatively rich. Among them, the hydrogen spectra of crude extract of fermentation broth of TSB-lactose and TSB-maltose were almost the same, with only some differences in the intensity of individual hydrogen signals. When sucrose was used as the carbon source, the crude extract of fermentation broth 1 The H-NMR spectrum is very similar to that of the fermentation products with lactose and maltose as carbon sources, but the δ H 7.11(t,6.0Hz),δ H 6.23(d,9.0Hz),δ H 5.20(d,3.6Hz),δ H 3.58(s) these four obvious hydrogen signals, and no δ H 6.31 (d, 1.8 Hz); the hydrogen signal of the crude extract of the glycerol-TSB medium fermentation broth is relatively small, but compared with the fermentation products of TSB-lactose and TSB-maltose, δ H 4.51(s),δ H 4.44(s),δ H There are characteristic hydrogen signals at 3.28-3.47 (m); when glucose is used as the carbon source, the fermentation products are similar to those of lactose-TSB and maltose-TSB, and the main difference is that H 2.10(s),δ H 2.09(d,3.6Hz),δ H There is a characteristic signal at 1.96(s), and no δ is observed. H 3.75(s),δ H2.16(s), there are also some differences in signal strength; when sodium citrate is used as the carbon source, the fermentation products are also similar to those of TSB-lactose and TSB-maltose. H 7.13(s),δ H 7.12(s),δ H 7.00(s),δ H There is a characteristic absorption signal at 6.18 (d, 8.4 Hz). In addition, there are also some differences in the strength of the signal.
[0041] (3) LC-MS / MS spectral analysis of crude extract of P. protegens FD6 rpoS mutant fermentation broth
[0042] The crude extracts of the fermentation broth of P.protegens FD6 rpoS mutant strain grown in 6 different carbon source culture media were sampled (about 1 mg / mL) and the LC-MS / MS spectra were determined.
[0043] UPLC conditions: Atlantis T3 column (2.1 mm × 100 mm, 3 μm), flow rate 0.3 mL / min, injection volume 3 μL. 0.1% formic acid-water as mobile phase A, methanol as mobile phase B, elution gradient: 0 min, 65% A; 7 min, 45% A; 13 min, 30% A; 17 min, 20% A; 27 min, 5% A; 30 min, 2% A.
[0044] LC-MS / MS conditions: electrospray ion source (ESI), positive ion scan mode; primary mass spectrometry scan range m / z 100-2000, secondary mass spectrometry scan range m / z 50-2000. Spray voltage: 5500 V; ion source temperature: 550 °C; curtain gas pressure: 35 psi; nebulizer gas pressure: 55 psi; auxiliary gas pressure: 55 psi; declustering voltage: 80 V; collision energy: 35 ev; ion release delay: 30 V; ion release width: 15 V.
[0045] Figure 4 These are LC-MS graphs of crude extracts from fermentation broths of various culture media, wherein Graph A is an XWC graph (Extract Wavelength Chromatogram) and Graph B is a BPC graph (Base Peak Chromatogram). Figure 4A shows that when sucrose, lactose, maltose and glycerol are added as carbon sources, the chromatographic peaks of the crude extracts of each fermentation broth are basically the same, but the strengths are different, mainly appearing at retention times of 0.9-4.0 min and 6.1-7.1 min; the chromatographic peaks of the crude extract of TSB-sodium citrate medium fermentation broth are similar to the above four culture medium products, but the chromatographic peak with a retention time of 6.5 min is not observed; the chromatographic peaks of TSB-glucose medium products are also similar to the above five culture medium products, but there are differences in the strength of the chromatographic peaks. In addition, it has a characteristic chromatographic peak with a retention time of 4.8 min. Figure 4 B shows that when sucrose, lactose, maltose and glycerol are added as carbon sources, the ion peak signals of the crude extracts of each fermentation broth are relatively abundant and basically the same, mainly appearing at retention times of 0.5-9.2min, 18.8-22.8min, and 24.8-28.5min, especially at 6.6min, there is a strong ion peak signal m / z 137.0235; the ion peak signal of the fermentation product of TSB-sodium citrate medium is similar to the above four culture medium products, but the ion peak at retention time of 6.6min is not observed, and some weak ion signals are missing; the ion peak signal of the fermentation product of TSB-glucose medium is relatively abundant, but relatively weak, and has certain similarities with the other five culture medium products, but the signal is slightly less.
[0046] Example 2 Inhibitory effect of crude extract of fermentation broth of Pseudomonas protegens FD6 rpoS mutant on proliferation of human non-small cell lung cancer cell line A549
[0047] 1. Instruments and Materials
[0048] Bio-Tek SYNERGY2 microplate reader (BioTek Co., Ltd., USA); Thermo SeriesⅡCO2 constant temperature incubator (Thermo Fisher Scientific, USA); 541D small high-speed centrifuge (Eppendorf, Germany); CX-23 inverted microscope (Olympus, Japan), etc.
[0049] Human non-small cell lung cancer cell line A549 (Shanghai Institutes for Biological Sciences Cell Bank); RPMI-1640 culture medium (Gibco, USA); fetal bovine serum (Nanjing Bio-Channel); penicillin-streptomycin mixture (Israel Biological Industries); 0.25% trypsin (Shanghai Bio-Tech Biotechnology Co., Ltd.); PBS (Jiangsu Keygen Biotechnology Co., Ltd.); mesothiocyanate (MTT) (Beijing Solebold Technology Co., Ltd.); cisplatin injection (Cisplatin) (production batch number: 181103, Jiangsu Hausen Pharmaceutical Co., Ltd.); DMSO (analytical grade, Sinopharm Chemical Reagent Co., Ltd.), etc.
[0050] 2MTT assay to determine the in vitro cytotoxic activity of fermentation products
[0051] The fermentation product of P.protegens FD6 rpoS mutant strain is dissolved in culture medium [RPMI-1640 culture medium: fetal bovine serum: penicillin-streptomycin mixture (v:v:v) 89:10:1] and diluted into a working solution of a certain concentration (a small amount of DMSO is used to assist dissolution, and the final concentration of DMSO should not exceed 0.1%), and is prepared and used immediately.
[0052] The in vitro cytotoxic activity of the samples was determined by MTT method, and cisplatin was used as positive control. The cell suspension in logarithmic growth phase was taken and 1.0×10 4 Cells / well were inoculated in a 96-well plate and cultured in a constant temperature incubator at 37°C and 5% CO2 for 24h. A certain concentration of sample solution or positive control drug was added to each well, and 100μL culture medium was added to the negative control group and the blank control group (5 replicate wells were set in the experiment). After 48h of culture, 10μL MTT (final concentration of 5mg / mL) was added to each well, and the culture was continued for 4h, then the culture medium was discarded, 100μL DMSO was added to each well, and the crystals were fully dissolved by shaking at 37°C for 10min. The absorbance value of each well was measured by an enzyme marker at a wavelength of 490nm. The experiment was repeated three times, and the experimental results were expressed as mean±SD; Graphpad Prism was used for one-way analysis of variance, and Tukey test was used for comparison between groups. P<0.05 was significantly different, P<0.01 was very significantly different, and P<0.001 was extremely significantly different.
[0053] The results showed that when maltose and glycerol were used as carbon sources, the crude extract of the fermentation broth of the FD6 ropS mutant strain had significant in vitro cytotoxic activity against A549 cells in a dose-effect relationship; at a concentration of 100 μg / mL, the proliferation inhibition rates of the fermentation products of these two carbon source mediums on A549 cells were 72.77%±8.19% and 75.02%±1.06%, respectively, and the IC 50The values were 22.62±9.80 and 25.59±4.05 μg / mL (the IC 50 The value was 6.22±4.72μg / mL)( Figure 5 ). In addition, at a concentration of 200 μg / mL, the crude extracts of fermentation broth of TSB-sucrose and TSB-lactose had an inhibitory effect on the proliferation of A549 cells of 36.36%±12.12% and 47.16%±3.72%, respectively, while the crude extracts of fermentation broth of TSB-glucose and TSB-sodium citrate had only a weak inhibitory effect on the proliferation of A549 cells, with inhibition rates of 14.21%±4.57% and 2.14%±8.46%, respectively.
Claims
1. A crude extract of fermentation broth of P. protegens FD6 rpoS mutant, characterized in that Prepared by the following method: (1) A single colony of the P. protegens FD6 rpoS mutant was inoculated into LB medium and cultured at 28°C and 180 rpm for 24 h to obtain a seed solution for later use; (2) inoculating the seed solution obtained in step (1) into TSB basal medium supplemented with different carbon sources at an inoculum rate of 1‰, and culturing at room temperature to 30°C for 36-60 hours to obtain a fermentation broth; (3) The fermentation broth obtained in step (2) is centrifuged at 4° C. and 9000-10000 rpm for 10-15 min, the supernatant is collected, extracted with ethyl acetate 2-3 times, and concentrated under reduced pressure to obtain the crude extract of the fermentation broth of the P. protegens FD6 rpoS mutant strain.
2. The crude extract according to claim 1, characterized in that The formula of the TSB basic culture medium is as follows: 15g of tryptone, 5g of soy peptone, 5g of NaCl per liter of water, and pH=7.0-7.
2.
3. The crude extract according to any one of claims 1 to 2, characterized in that The carbon source is selected from one of sucrose, lactose, maltose, glucose, glycerol and sodium citrate, and the amount of the carbon source is 2%-3% of the mass of the basic culture medium.
4. The crude extract according to any one of claims 1 to 3, characterized in that The preferred carbon sources are maltose and glycerol.
5. The crude extract according to any one of claims 1 to 4, characterized in that The crude extract of the fermentation broth of the P. protegens FD6 rpoS mutant 1 The H-NMR graph is basically as shown in FIG3 .
6. The crude extract according to any one of claims 1 to 5, characterized in that The LC-MS graph of the crude extract of the fermentation broth of the P. protegens FD6 rpoS mutant strain is basically as shown in Figure 4.
7. The method for preparing the crude extract according to any one of claims 1 to 6, characterized in that The steps include: (1) A single colony of the P. protegens FD6 rpoS mutant was inoculated into LB medium and cultured at 28°C and 180 rpm for 24 h to obtain a seed solution for later use; (2) The seed liquid obtained in step (1) is inoculated into TSB basal medium supplemented with different carbon sources at an inoculum amount of 1‰, and cultured at room temperature to 30°C for 36-60 hours to obtain a fermentation liquid. (3) The fermentation broth obtained in step (2) is centrifuged at 4° C. and 9000-10000 rpm for 10-15 min, the supernatant is collected, extracted with ethyl acetate 2-3 times, and concentrated under reduced pressure to obtain the crude extract of the fermentation broth of the P. protegens FD6 rpoS mutant strain.
8. Use of the crude extract according to any one of claims 1 to 6 in the preparation of anti-tumor drugs.
9. A composition characterized in that The composition uses the crude extract described in any one of claims 1 to 6 as an active ingredient.
10. The composition of claim 9, characterized in that Other anti-tumor drugs may also be included; the composition may also contain pharmaceutically acceptable salts; the dosage form of the composition is selected from solid preparations, liquid preparations or semi-solid preparations.
